Carl L. Gordon

Carl L. Gordon has served as a member of the board of directors since March 2020. Since 1995 Dr. Gordon has been a member of OrbiMed Advisors LLC, an investment firm where he is a Founding Partner and Co-Head of Global Private Equity. Dr. Gordon currently serves on the boards of directors of Turning Point Therapeutics and Prevail Therapeutics, as well as several private companies. Dr. Gordon previously served on the boards of directors of several biopharmaceutical companies, including Alector, X4 Pharmaceuticals (formerly Arsanis), Acceleron Pharma, ARMO Biosciences, Intellia Therapeutics, Selecta Biosciences and Passage Bio. Prior to OrbiMed, Dr. Gordon served as a senior biotechnology analyst at Mehta and Isaly Asset Management and was a Fellow at The Rockefeller University. Dr. Gordon received a B.A. in Chemistry from Harvard College and a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology.